Hangzhou Tigermed Consulting stock
300347.SZSHZHangzhou Tigermed Consulting Co., Ltd, HealthcareISIN CNE100001KV8
46Score 46 out of 100, Weak
Price and trend
61 / 100
Price history
−15% in one yearThe chart shows daily closes over 14 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 6.3% below it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 50).
The price is 27% below its 52-week high. Largest decline in 14 years: 82% (July 2021 to June 2026).
Chart figures for advanced users
- SMA 50$7.92
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$7.83
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)50
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$5.42
- The lowest closing price of the last twelve months.
- Resistance$9.99
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Hangzhou Tigermed Consulting Co., Ltd belongs to the Biotechnology industry (China) and, with a market value of $6.12B, is number 65 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.02B (up 3.5% year on year) and earnings of $133.15M (up 119.2%).
- For fiscal 2026, analysts expect on average revenue of $1.17B (up 14.2%) and adjusted earnings per share of $0.07 (down 54.1%).
Show more
- MEQIRI Score 46 out of 100 (Weak): rank 430 of 702 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 73
- More cash than debtCash $317.67M, financial debt $314.4M.Stability 74
Weaknesses
- Margin fallingOperating margin 14.8%, average of the prior years 36.4% (to 2024).Profitability 20
- Loss-makingLoss of $60.67M over the last 12 months.
- Earnings per share fallingDown 13.9% a year since 2020.Growth 50
Its standout strengths are stability and fundamentals, while capital allocation and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 46.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
OvervaluedA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 15.8% on the twelve months before. Revenue has grown strongly since 2009, at around 34% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 27%, operating 15%, net 13%. Last 12 months: net −5%.
Debt & balance sheet
latest quarterLow debt, and interest is adequately covered.
Earnings
- Next earnings
- 29 Mar 2027in 136 days
- Last reported
- 29 Oct 2026EPS reported $0.03 (expected $0.05)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 9.6% since 25 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.07−9.6%
- Revenue
- $1.17B+0.5%
- Earnings per share
- $0.20+0.5%
- Revenue
- $1.36B+1.0%
MEQIRI has stored the estimates since 25 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Hangzhou Tigermed Consulting
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- BioconBIOCON.NS $6.42B41
- Samsung Epis Holdings0126Z0.KS $6.4B41
- Ligand PharmaceuticalsLGND $6.33B60
- CG OncologyCGON $6.27B41
- Mirum PharmaceuticalsMIRM $6.09B38
- Scholar Rock HoldingSRRK $5.71B35
- Anthem BiosciencesANTHEM.NS $5.62B78
- Shanghai Allist Pharmaceuticals688578.SS $5.61B66
ETFs that hold Hangzhou Tigermed Consulting
Held by 56 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| JPMorgan Global Emerging Markets Research Enhanced Index Equity Active UCITS ETFJREM | 0.15% | 0.30% | €2.46B |
| Amundi MSCI Emerging Markets SRI Climate Paris Aligned UCITS ETF DR (C)AMEI | 0.13% | 0.25% | €2.64B |
| Xtrackers Harvest CSI A500 UCITS ETF 1DAH50 | 0.11% | 0.65% | €10.81M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 0.07% | 0.40% | €1.5B |
| HSBC MSCI China A UCITS ETF USDH41K | 0.05% | 0.30% | €68.31M |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.43B |
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.02% | 0.30% | €132.6M |
| Amundi MSCI China ESG Selection Extra UCITS ETF AccLCHI | 0.01% | 0.65% | €564.13M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 16 Oct 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.